검색어 : 통합검색[Hartley Marsden]
총 93건 중 93건 출력
, 9/10 페이지
-
81
- Clinical trial management: a profession in crisis?
- Mitchell, E. J.; Goodman, K.; Wakefield, N.; Cochran, C.; Cockayne, S.; Connolly, S.; Desai, R.; Hartley, S.; Lawton, S. A.; Oatey, K.; Rhodes, S.; Savage, J. S.; Taylor, J.; Youssouf, N. F. J.; Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, University Park, Nottingham, NG7 2RD UK; NMAHP Research Unit, Glasgow Caledonian University, Glasgow, G4 0NA UK; Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, University Park, Nottingham, NG7 2RD UK; Centre for Healthcare and Randomised Controlled Trials (CHaRT), Health Services Research Unit, University of Aberdeen, Aberdeen, AB23 2ZD UK; York Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD UK; Royal Marsden Clinical Trials Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ UK; King’s Ophthalmology Research Unit, King’s College Hospital, London, SE5 9RS UK; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT UK; Keele Clinical Trials Unit, School of Medicine, Keele University, Keele, ST5 5BG UK; Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh,; (Trials, v.23, 2022, pp.357)
-
82
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
- Lee, Lennard YW; Cazier, Jean-Baptiste; Angelis, Vasileios; Arnold, Roland; Bisht, Vartika; Campton, Naomi A; Chackathayil, Julia; Cheng, Vinton WT; Curley, Helen M; Fittall, Matthew W; Freeman-Mills, Luke; Gennatas, Spyridon; Goel, Anshita; Hartley, Simon; Hughes, Daniel J; Kerr, David; Lee, Alvin JX; Lee, Rebecca J; McGrath, Sophie E; Middleton, Christopher P; Murugaesu, Nirupa; Newsom-Davis, Thomas; Okines, Alicia FC; Olsson-Brown, Anna C; Palles, Claire; Pan, Yi; Pettengell, Ruth; Powles, Thomas; Protheroe, Emily A; Purshouse, Karin; Sharma-Oates, Archana; Sivakumar, Shivan; Smith, Ashley J; Starkey, Thomas; Turnbull, Chris D; Vá rnai, Csilla; Yousaf, Nadia; Kerr, Rachel; Middleton, Gary; Institute of Cancer and Genomic Sciences, University of Birmingham; Institute of Cancer and Genomic Sciences, University of Birmingham; The Royal Marsden Hospital NHS Foundation Trust; Institute of Cancer and Genomic Sciences, University of Birmingham; Centre for Computational Biology, University of Birmingham; Institute of Translational Medicine, Birmingham Health Partners; Cancer Research Clinical Research Facility, St George's University Hospitals NHS Foundation Trust; Leeds Institute of Medical Research, University of Leeds; Institute of Cancer and Genomic Sciences, University of Birmingham; The Royal Marsden Hospital NHS Foundation Trust; Glasgow Royal Infirmary; The Royal Marsden Hospital NHS Foundation Trust; (The Lancet, v.395, 2020, pp.1919-1926)
-
83
- ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.
- Forster, Martin David; Mendes, Ruheena; Harrington, Kevin J.; Guerrero Urbano, Teresa; Baines, Helen; Spanswick, Victoria J; Ensell, Leah; Hartley, John A.; Adeleke, Sola; Gougis, Paul; Leader, David; McDowell, Cathy; Lopes, Andre; Teague, Jonathan; Forsyth, Sharon; Beare, Sandy; University College London, London, United Kingdom; ; University College London Hospital, London, United Kingdom; ; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; ; Guy's and St Thomas' Hospitals, London, United Kingdom; ; RTTQA Royal Marsden, London, United Kingdom; ; University College London Cancer Institute, London, United Kingdom; ; University College London Cancer Institute, London, United Kingdom; ; University College London, London, United Kingdom; ; University College London, London, United Kingdom; ; University College London Hospital, London, United Kingdom; ; University College London Hospital, London, United Kingdom; ; Combinations Alliance, Cancer Research UK, London, United Kingdom; ; Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom; ; Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom; ; Cancer Research UK & University College London Cancer Trials Centr; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.34, 2016, pp.TPS6108-TPS6108)
-
84
- A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
- Taylor, Graham S.; Jia, Hui; Harrington, Kevin; Lee, Lip Wai; Turner, James; Ladell, Kristin; Price, David A.; Tanday, Manjit; Matthews, Jen; Roberts, Claudia; Edwards, Ceri; McGuigan, Lesley; Hartley, Andrew; Wilson, Steve; Hui, Edwin P.; Chan, Anthony T. C.; Rickinson, Alan B.; Steven, Neil M.; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.; Division of Cancer Biology, The Institute of Cancer Research/The Royal Marsden Hospital, London, United Kingdom.; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.; Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.; Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.; Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.; Division of Cancer Biology, The Institute of Cancer Research/The Royal Marsden Hospital, London, United Kingdom.; Cancer Research UK Centre,; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.20, 2014, pp.5009-5022)
-
85
- Research priorities for children’s cancer: a James Lind Alliance Priority Setting Partnership in the UK
- Aldiss, Susie; Hollis, Rachel; Phillips, Bob; Ball-Gamble, Ashley; Brownsdon, Alex; Chisholm, Julia; Crowther, Scott; Dommett, Rachel; Gower, Jonathan; Hall, Nigel J; Hartley, Helen; Hatton, Jenni; Henry, Louise; Langton, Loveday; Maddock, Kirsty; Malik, Sonia; McEvoy, Keeley; Morgan, Jessica Elizabeth; Morris, Helen; Parke, Simon; Picton, Sue; Reed-Berendt, Rosa; Saunders, Dan; Stewart, Andy; Tarplee-Morris, Wendy; Walsh, Amy; Watkins, Anna; Weller, David; Gibson, Faith; School of Health Sciences, University of Surrey, Guildford, UK; Leeds Children's Hospital, Leeds, UK; Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Children’s Cancer and Leukaemia Group, Leicester, UK; Patient Representative on the Children’s Cancer Priority Setting Partnership Steering Group, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK; Parent Representative on the Children’s Cancer Priority Setting Partnership Steering Group, Coventry, UK; Bristol Royal Hospital for Children, Bristol, UK; James Lind Alliance, National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre, Southampton, UK; Southampton Children's Hospital, Southampton, UK; Alder Hey Children's NHS Foundation Trust, Liverpool, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK; Parent Representative on the Children’s Cancer Priori; (BMJ open, v.13, 2023, pp.e077387-e077387)
-
86
- The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (<small>HNSCC</small>) in the <small>UK</small>
- Vasiliadou, Ifigenia; Grose, Derek; Wilson, Christina; Thapa, Alekh; Donnelly, Olly; Lee, Elsa; Leslie, Isla; Karim, Mahwish; Hartley, Andrew; Partridge, Sarah; Medlow, Katharine; De Boisanger, James; Metcalf, Robert; Williamson, Andrew; Haridass, Anoop; Noble, David; Mactier, Karen; Walter, Harriet; Ma, Ning; De Winton, Emma; Cohen, Jennifer; Rayner, Lindsay; Geropantas, Konstantinos; Jankowska, Petra; Mason, Jessica; Moleron, Rafael; Laws, Kirsten; Ulahannan, Danny; Nallathambi, Chandran; Michaelidou, Andriana; Nallamilli, Susanna; Raouf, Sherif; Palmer, Kieran; Bienz, Maya; Karet, Tracy; Khalique, Saira; Paterson, Claire; Harrington, Kevin; Bhide, Shreerang; Kong, Anthony; Guy's and St. Thomas NHS Foundation Trust London UK; Beatson West of Scotland Cancer Centre Glasgow UK; Beatson West of Scotland Cancer Centre Glasgow UK; Beatson West of Scotland Cancer Centre Glasgow UK; Portsmouth Hospitals NHS Trust Portsmouth Hampshire UK; Guy's and St. Thomas NHS Foundation Trust London UK; Royal Marsden NHS Foundation Trust London UK; Royal Marsden NHS Foundation Trust London UK; Queen Elizabeth Hospital Birmingham Birmingham UK; Imperial College Healthcare NHS Trust-Charing Cross Hospital London UK; Imperial College Healthcare NHS Trust-Charing Cross Hospital London UK; Imperial College Healthcare NHS Trust-Charing Cross Hospital London UK; The Christie NHS Foundation Trust Manchester UK; The Christie NHS Foundation Trust Manchester UK; The Clatterbridge Cancer Centre Liverpool UK; Edinburgh Cancer Centre Edinburgh UK; Edinburgh Cancer Centre Edinburgh UK; University Hospitals of Leicester Leicester UK; University Hospitals of Leicester Leices; (International journal of cancer: Journal international du cancer, v.155, 2024, pp.883-893)
-
87
- <I>BRCA1</I>, <I>BRCA2</I> and <I>TP53</I> mutations in very early-onset breast cancer with associated risks to relatives
- Lalloo, Fiona; Varley, Jennifer; Moran, Anthony; Ellis, David; O’ Dair, Lindsay; Pharoah, Paul; Antoniou, Antonis; Hartley, Roger; Shenton, Andrew; Seal, Sheila; Bulman, Barbara; Howell, Anthony; Evans, D. Gareth R.; ; (European journal of cancer, v.42, 2006, pp.1143-1150)
-
88
- Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma
- Clement, S.C.; Schoot, R.A.; Slater, O.; Chisholm, J.C.; Abela, C.; Balm, A.J.M.; van den Brekel, M.W.; Breunis, W.B.; Chang, Y.C.; Davila Fajardo, R.; Dunaway, D.; Gajdosova, E.; Gaze, M.N.; Gupta, S.; Hartley, B.; Kremer, L.C.M.; van Lennep, M.; Levitt, G.A.; Mandeville, H.C.; Pieters, B.R.; Saeed, P.; Smeele, L.E.; Strackee, S.D.; Ronckers, C.M.; Caron, H.N.; van Santen, H.M.; Merks, J.H.M.; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands; Department of Pediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; Children and Young People's Department, Royal Marsden Hospital, Sutton, United Kingdom; Craniofacial Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pediatric Oncology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Departme; (European journal of cancer, v.54, 2016, pp.1-10)
-
89
- PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT).
- Mehanna, Hisham Mohamed; Wong, Wai Lup; McConkey, Christopher C; Rahman, Joy K; Robinson, Max; Hartley, Andrew G. J.; Nutting, Christopher; Powell, Ned; Al-Booz, H; Robinson, Martin; Junor, Elizabeth; Hulme, Claire; Smith, Alison Florence; Hall, Peter; Dunn, Janet; InHANSE, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, United Kingdom; Warwick University Clinical Trials Unit, Coventry, United Kingdom; Warwick University Clinical Trials Unit, Coventry, United Kingdom; Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; Royal Marsden Hospital, London, United Kingdom; HPV Oncology Group, Institute of Cancer and Genetics, Cardiff University, Cardiff, United Kingdom; Bristol Haematology and Oncology Centre, Bristol, United Kingdom; Weston Park Hospital, Sheffield, United Kingdom; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; University of Leeds, Leeds, United Kingdom; University of Leeds, Leeds, United Kingdom; St James University Hospital, Leeds, United Kingdom; Warwick University Clinical Trials Unit, Coventry, United; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.33, 2015, pp.6009-6009)
-
90
- A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic
- Vasiliadou, Ifigenia; Noble, David; Hartley, Andrew; Moleron, Rafael; Sanghera, Paul; Urbano, Teresa Guerrero; Schipani, Stefano; Gujral, Dorothy; Foran, Bernie; Bhide, Shree; Haridass, Anoop; Nathan, Kannon; Michaelidou, Andriana; Sen, Mehmet; Geropantas, Konstantinos; Joseph, Mano; O'Toole, Lorcan; Griffin, Matthew; Pettit, Laura; Chambers, Jonathan; Jankowska, Petra; De Winton, Emma; Goranova, Rebecca; Singh, Niveditha; Shah, Ketan; Kong Conceptualisation, Anthony; Guy’s and St, Thomas NHS Foundation Trust; Edinburgh Cancer Centre; Queen Elizabeth Hospital Birmingham; Aberdeen Royal Infirmary; Queen Elizabeth Hospital Birmingham; Guy’s and St, Thomas NHS Foundation Trust; Beatson West of Scotland Cancer Centre; Imperial College Healthcare NHS Trust; ; Royal Marsden NHS Foundation Trust; Clatterbridge Cancer Centre; Kent Oncology Centre, Maidstone and Canterbury; Kent Oncology Centre, Maidstone and Canterbury; Leeds Cancer Centre; Nortfolk and Norwich University; (Clinical and translational radiation oncology, v.30, 2021, pp.50-59)
QUICK MENU
